BIOMARK Laboratories-INDIA www.biomarklabs.com

TECHNICAL SHEET

BDR006

Gram positive ring

SPECIFICATIONS:

COLOUR: White ring having 12 discs of 6 mm diameter each with abbreviation in red

DIRECTIONS:

- 1. Prepare sterile plates of Mueller Hinton Agar (B263).
- 2. Prepare inoculum as per Bauer-Kirby Method-make a pure inoculum of culture. Inoculate pure single colony of test organism *E. coli* (ATCC 25922), *S. aureus* (25923) and *P. aeruginosa* (27853), in 5ml Pre tested sterile SCDM (B040) in a test tube & incubate at 36 to 37°C for 2 hours. Compare the inoculum turbidity with that of standard 0.5McFARLAND STANDARD (BA 132).
- 3. Dip a sterile swab into the standardized inoculum and press against the wall of the test tube to remove excess liquid.
- 4. Swab the plates by rotating in all directions till the plate becomes dry.
- 5. Place the antimicrobial ring on the swabbed plates aseptically with the help of alcohol dipped flame sterilized forceps. Press the ring properly on the plates.
- 6. Incubate the plates at 36°C 37°C for 18- 24 hours.
- 7. Measure the zones showing complete inhibition and record the diameters of the zones to the nearest millimetre using a calibrated instrument like zone scales.

RESULTS: Average diameter of zone of inhibition is observed on Mueller Hinton Agar (B263) after 18-24 hours incubation at 36°C -37°C for standard cultures.

Antimicrobial agent, micro-	Diameter of zone of inhibition				
organism with ATCC number	Interpretative criteria			Quality	
	Sensitive	Intermediate	Resistant	control	
	mm or more	mm	mm or less	limit in mm	
Amoxycillin- clavulanate					
30mcg AUG					
EC (ATCC 25922)	18	14-17	13	18-24	
SA (ATCC 25923)	20		19	28-36	
PS (ATCC 27853)					
Cefotaxime 25mcg CTX					
EC (ATCC 25922)					
SA (ATCC 25923)					
PS (ATCC 27853)					
Ceftriaxone-sulbactam 45mcg					
CRO					
EC (ATCC 25922)					
SA (ATCC 25923)					
PS (ATCC 27853)					
Cefixime 5mcg ZEM					
EC (ATCC 25922)	19	16-18	15	23-27	
SA (ATCC 25923)					
PS (ATCC 27853)					
Levofloxacin 5mcg LBC	47	4446	4.0	20.27	
EC (ATCC 25922)	17	14-16	13	29-37	
SA (ATCC 25923)	19	16-18	15	25-30	
PS (ATCC 27853)	17	14-16	13	19-26	
Ciprofloxacin 5mcg CIP	24	16.20	4.5	20.40	
EC (ATCC 25922)	21	16-20	15	30-40	
SA (ATCC 25923)	21	16-20	15	22-30	
PS (ATCC 27853)	21	16-20	15	25-33	

Rev: December 2024

BIOMARK Laboratories-INDIA

www.biomarklabs.com

TECHNICAL SHEET

Imipenem/cilastatin 10/10ug				
IMP				
EC (ATCC 25922)	23	20-22	19	26-32
SA (ATCC 25923)	16	14-15	13	
PS (ATCC 27853)	19	16-18	15	20-28
Cefuroxime 30mcg CXM				
EC (ATCC 25922)	18	15-17	14	20-26
SA (ATCC 25923)	18	15-17	14	27-35
PS (ATCC 27853)				
Ofloxacin 5mcg OFX				
EC (ATCC 25922)	16	13-15	12	29-33
SA (ATCC 25923)	18	15-17	14	24-28
PS (ATCC 27853)	16	13-15	12	17-21
Erythromycin 15mcg ERY				
EC (ATCC 25922)				
SA (ATCC 25923)	23	14-22	13	22-30
PS (ATCC 27853)				
Gentamicin 10 mcg GN				
EC (ATCC 25922)	15	13-14	12	19-26
SA (ATCC 25923)	15	13-14	12	19-27
PS (ATCC 27853)	15	13-14	12	16-21
Azithromycin 15mcg AZN				
EC (ATCC 25922)				
SA (ATCC 25923)	18	14-17	13	21-26
PS (ATCC 27853)				

USE: It is used for antimicrobial sensitivity for relevant test organisms for laboratory diagnosis.

Precautions: For Laboratory Use.

Storage: -20 to 8°C

Packing: 50 Rings Pack

Disclaimer:

User must ensure suitability of the product(s) in their application prior to use. Products conform solely to the information contained in this and other related BIOMARKLABORATORIES publications.

The information contained in this publication is based on our in-house studies and market performance and is to the best of our knowledge true and accurate. BIOMARK LABORATORIES reserves the right to make changes to specifications and information related to the products at any time. Products are not intended for human or animal or therapeutic use but for laboratory, diagnostic, research or further manufacturing use only, unless otherwise specified. Statements contained herein should not be considered as a warranty of any kind, expressed or implied, and no liability is accepted for infringement of any patents.

Rev: December 2024